Efficacy of temsirolimus versus pazopanib in the treatment of advanced renal cell carcinoma: a meta-analysis
Temsirolimus demonstrated greater efficacy in the low-risk group, while pazopanib was superior in the high-risk group for the treatment of RCC. Consideration of both efficacy and toxicity is crucial to guide drug selection for patients. TRN: CRD42024578497 (Registration date: 2024/08/21).
Authors
- Yanni Liu (ORCID: https://orcid.org/0000-0002-1042-6000)
Institutions
- Yantaishan Hospital (CN)
Publication Details
- Journal
- American Journal of Clinical and Experimental Urology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.62347/xjdw3310
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00